or
Bookmark and Share
   
Document Number
US Patent 3879546
Issued Date
April 22, 1975
Link
Inventors
Map
Abstract
This invention relates to the production of saccharase inhibitors in which a polysaccharidic or oligosaccharidic amylase inhibitor is hydrolytically degraded either enzymatically or by acid hydrolysis. The invention also relates to the use of said saccharase inhibitors in pharmaceutically acceptable therapeutic compositions in the treatment of conditions indicating adiposity, hyperlipaemia (atherosclerosis), diabetes, pre-diabetes, caries and the like.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
18
Comments:
no comments yet
Owner
Bayer Aktiengesellschaft (Leverkusen,DT)
Published
April 22, 1975
Application Number
05/336,720
Filed
February 28, 1973
US Classification
424/115   435/14 435/190 435/201 435/822 435/95
Int'l Classification
C12P   19/04   (20060101)   C12P   19/22   (20060101)   C12P   19/00   (20060101)  
Attorney/Law Firm
Priority Data
Mar 01, 1972 [DT] 2209832
USPTO Field of Search
195/8R   195/4   195/65   195/29   424/115  
Related Patents
4019960 - Process for the production of a saccharase inhibitor - Owned by Bayer Aktiengesellschaft (Leverkusen,DT) [*] Notice:The portion of the term of this patent subsequent to April 22, 1992 has been disclaimed.

The invention relates to a saccharase inhibitor derived from Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, means for the production of said saccharase inhibitors comprising cultivation of Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, in appropriate nutrient solutions which are characterized by being starch free under conditions most favorable to growth and production of said saccharase inhibitor and recovering a saccharase inhibitor from culture broths of said nutrient solutions, as well as the use of said inhibitor in pharmaceutically acceptable therapeutic compositions suitable for use in the treatment and relief of conditions indicative of adiposity, diabetes, pre-diabetes, hyperlipaemia (atherosclerosis), caries and the like.

4010258 - Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus - Owned by Ajinomoto Co., Inc. (Tokyo,JA) Eisai Co., Ltd. (Tokyo,JA)

A new amylase inhibitor, called Amylostatin-A, which can be distinguished from those disclosed heretofore on the basis of its constitution, molecular weight, specificity for certain types of amylase and adsorbability, is obtained by cultivating a strain of actinomycetes belonging to Streptomyces diastaticus var. amylostaticus FERM P-2499 in a medium containing starch, preferably amylopectin, as the sole source of carbon; the conditions of cultivation, methods of isolation and purification and therapeutical application thereof are disclosed.

6649755 - Process for preparing acarbose with high purity - Owned by Chong Kun Dang Pharmaceutical Corp. (Seoul,KR)

Disclosed herein is a process for preparing highly pure acarbose of formula (I) useful as medicine for the treatment of diabetes. The disclosed process comprises prepurifying an acarbose-containing solution using a synthetic adsorbent to produce a prepurified acarbose having an acarbose content of a predetermined level or more; and contacting the prepurified acarbose with a monodispersed, strongly acid cation exchanger, in one step, to absorb acarbose.

6734300 - Acarbose purification process - Owned by VA, Farmaceutska Industrija, DD (Zagreb,HR)

An improved process for the purification of crude aqueous solutions of acarbose by passing such solutions through a strong acid cation-exchange resin, saturating such resin and recovering as an eluate a substantially pure acarbose solution. Purities of more than 98%, and preferably about 99% or higher, are thus obtained.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us